4. 原発性側索硬化症 Primary lateral sclerosis Clinical trials / Disease details
臨床試験数 : 7 / 薬物数 : 17 - (DrugBank : 9) / 標的遺伝子数 : 19 - 標的パスウェイ数 : 32
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02868567 (ClinicalTrials.gov) | March 2016 | 17/3/2016 | Use of Dalfampridine in Primary Lateral Sclerosis | A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis | Motor Neuron Disease, Upper | Drug: dalfampridine | Weill Medical College of Cornell University | Hospital for Special Surgery, New York | Recruiting | 18 Years | 99 Years | All | 35 | Phase 1 | United States |